# Perrigo Company plc (PRGO) Stock Analysis: Exploring a Potential Upside of 77.64% Amidst Volatility

- Link: https://www.directorstalkinterviews.com/perrigo-company-plc-prgo-stock-analysis-exploring-a-potential-upside-of-77-64-amidst-volatility/4121246041
- Published: 2026-03-24T11:25:14+00:00
- Author: Madison Wilson

Perrigo Company plc (NYSE: PRGO), a prominent player in the healthcare sector, operates
within the niche of specialty and generic drug manufacturing. Headquartered in Dublin,
Ireland, Perrigo offers a plethora of over-the-counter health and wellness solutions
across the globe. With a market capitalization of $1.32 billion, the company serves
consumers through its Consumer Self-Care Americas and Consumer Self-Care International
segments, providing products ranging from respiratory aids to vitamins.

Currently trading at $9.57, Perrigo’s stock has experienced significant volatility,
as reflected in its 52-week range of $9.25 to $28.43. This fluctuation underscores
the challenges and opportunities facing the company. Despite a modest price change
of 0.32 (0.03%) recently, the broader picture paints a complex scenario for investors.

The valuation metrics for Perrigo are intriguing. Notably, the forward P/E ratio
stands at a compelling 3.95, suggesting that the stock is currently undervalued 
relative to its earnings potential. However, other metrics such as the trailing 
P/E, PEG ratio, and Price/Book are currently unavailable, which may pose a challenge
for investors seeking a comprehensive valuation picture.

Performance metrics reveal a mixed bag. Revenue growth has contracted by 2.50%, 
and the company is grappling with a negative EPS of -10.12. The return on equity
is starkly negative at -38.66%, reflecting challenges in generating profit from 
shareholder equity. Despite these hurdles, Perrigo maintains a positive free cash
flow of $28.33 million, a critical factor for sustaining operations and potential
growth initiatives.

One of the standout features of Perrigo’s financials is its dividend yield of 12.12%,
an attractive proposition for income-focused investors. However, the exceptionally
high payout ratio of 10,950.00% may raise concerns about the [sustainability](https://www.directorstalkinterviews.com/sustainability-green-stocks-news)
of such dividends in the long run.

Analyst sentiment towards Perrigo is cautiously optimistic. With two buy ratings,
three hold ratings, and no sell ratings, the consensus indicates a degree of confidence
in the company’s prospects. The target price range of $15.00 to $20.00 offers a 
potential upside of 77.64%, an enticing prospect for investors willing to ride out
the current volatility.

Technical indicators provide further insights. The stock is trading below its 50-
day and 200-day moving averages, at $13.07 and $18.99, respectively, signaling a
bearish trend. The Relative Strength Index (RSI) of 31.64 suggests that the stock
is approaching oversold territory, which could indicate a potential buying opportunity
for contrarian investors. Additionally, the MACD and signal line are closely aligned
at -1.12 and -1.13, respectively, pointing towards a possible trend reversal.

Perrigo’s extensive product portfolio, including well-known brands like Nasonex,
Plackers, and Mederma, positions it well in the competitive landscape of consumer
self-care products. Its diverse distribution channels, encompassing retail drug 
stores, supermarkets, e-commerce platforms, and pharmacies, provide a robust framework
for market penetration.

Founded in 1887, Perrigo’s long-standing presence in the industry is a testament
to its resilience and adaptability. As the company navigates current challenges,
investors will be keenly watching how it leverages its strengths to capitalize on
market opportunities and drive future growth. The potential for substantial upside,
paired with a high dividend yield, makes Perrigo a stock worth considering for those
with a balanced appetite for risk and reward.

Share on: